<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37772">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614794</url>
  </required_header>
  <id_info>
    <org_study_id>ONT-380-206</org_study_id>
    <nct_id>NCT02614794</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine &amp; Trastuzumab in Patients With Advanced HER2+ Breast Cancer</brief_title>
  <acronym>HER2CLIMB</acronym>
  <official_title>Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cascadian Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cascadian Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of tucatinib vs. placebo in combination
      with capecitabine and trastuzumab on progression-free survival (PFS) per RECIST 1.1 based on
      independent central review.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, international, multi-center, double-blinded study in patients with pretreated
      unresectable locally advanced or metastatic HER2+ breast cancer who have had prior treatment
      with a taxane, trastuzumab, pertuzumab and T-DM1. Patients will be randomized in a 2:1 ratio
      to receive tucatinib or placebo in combination with capecitabine and trastuzumab.

      Stratification factors include presence or history of treated or untreated brain metastases
      (yes/no), Eastern Cooperative Oncology Group Performance Status (ECOG PS) (0 vs. 1), and
      region of world (US vs Canada vs Rest of World).

      No crossover from placebo to tucatinib will be allowed.

      Safety assessments will be performed at a minimum of once every three weeks throughout study
      treatment and 30 days after the last dose of study drugs. Laboratory assessments will be
      performed locally at sites. Cardiac ejection fraction will be assessed by MUGA/ECHO at
      screening and once every 12 weeks thereafter.

      Brain MRI will be performed at baseline in all patients. Efficacy assessments utilize RECIST
      1.1 and should include measurement of all known sites of metastatic or locally advanced
      unresectable disease at baseline, every 6 weeks for the first 24 weeks, and then every 9
      weeks thereafter. Repeat MRI of the brain will be required on this same schedule only in
      those patients with brain metastases. All treatment decisions will be made based upon
      investigator assessment of radiologic scans. All patients will undergo a repeat MRI of the
      brain within 30 days of the end of treatment. Patients in both arms of the study will
      continue to be followed for OS after completion of study treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) per RECIST 1.1 based on independent central review</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of tucatinib in combination with capecitabine and trastuzumab on overall survival (OS)</measure>
    <time_frame>52 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) in the subgroup of patients with baseline brain metastases per RECIST 1.1 based on central review</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>HER2 Positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tucatinib in combination with capecitabine &amp; trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo in combination with capecitabine &amp; trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tucatinib</intervention_name>
    <description>Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.</description>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <other_name>ONT-380</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.</description>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.</description>
    <arm_group_label>Tucatinib in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.</description>
    <arm_group_label>Placebo in combination with capecitabine &amp; trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Have histologically confirmed HER2+ breast carcinoma, with HER2+ defined by fluorescence
        in situ hybridization (FISH) and/or 3+ staining by immunohistochemistry (IHC)

        Have received previous treatment with a taxane, trastuzumab, pertuzumab, and T-DM1

        Have progression of unresectable locally advanced or metastatic breast cancer after last
        systemic therapy (as confirmed by investigator), or be intolerant of last systemic therapy

        Have measurable or non-measurable disease assessable by RECIST 1.1

        Be at least 18 years of age at time of consent

        Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1

        Have adequate hepatic and renal function

        Have left ventricular ejection fraction (LVEF) â‰¥ 50%

        CNS Inclusion - Based on screening brain magnetic resonance imaging (MRI), patients must
        have one of the following:

        No evidence of brain metastases

        Untreated brain metastases not needing immediate local therapy

        Previously treated brain metastases

          1. Brain metastases previously treated with local therapy may either be stable since
             treatment or may have progressed since prior local CNS therapy

          2. Patients treated with CNS local therapy for newly identified lesions found on initial
             MRI performed during screening for this study may be eligible to enroll if all of the
             following criteria are met:

        i. Time since whole brain radiation therapy (WBRT) is &gt; 21 days prior to first dose of
        study treatment, time since stereotactic radiosurgery (SRS) is &gt; 7 days prior to first
        dose of study treatment, or time since surgical resection is &gt; 28 days

        ii. Other sites of evaluable disease are present

        c. Relevant records of any CNS treatment must be available to allow for classification of
        target and non-target lesions

        Exclusion Criteria

        Have previously been treated with:

          1. lapatinib within 12 months of starting study treatment or

          2. neratinib, afatinib, or other investigational HER2/epidermal growth factor receptor
             (EGFR) or HER2 tyrosine kinase inhibitor (TKI) at any time previously

        Have previously been treated with capecitabine for metastatic disease. Note: Patients who
        have received capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior
        to starting study treatment are eligible.

        Have clinically significant cardiac disease

        Are known carriers of Hepatitis B or Hepatitis C or have other known chronic liver disease

        Are known to be positive for human immunodeficiency virus (HIV)

        Unable for any reason to undergo MRI of the brain

        CNS Exclusion - Based on screening brain MRI, patients must not have any of the following:

        Any untreated brain metastases &gt; 2.0 cm in size, unless discussed with medical monitor

        Ongoing use of systemic corticosteroids for control of symptoms of brain metastases at a
        total daily dose of &gt; 2 mg of dexamethasone (or equivalent)

        Any lesion thought to require immediate local therapy. Patients who undergo local
        treatment for such lesions identified by screening MRI may still be eligible for the study
        based on criteria described under CNS inclusion criteria

        Known or concurrent leptomeningeal disease (LMD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luke Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cascadian Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Witherspoon</last_name>
      <email>fwithers@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Erica Stringer-Reasor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Alabama (USA) - Mitchell Cancer Institute (MCI)</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pam Francisco</last_name>
      <email>pfrancisco@health.southalabama.edu</email>
    </contact>
    <investigator>
      <last_name>Carole Norden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Rocha</last_name>
      <phone>310-633-8400</phone>
      <email>mprocha@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Hurvitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy DeLuca</last_name>
      <email>Amy.Deluca@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Jo Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desiree Goldstein</last_name>
      <email>desiree.goldstein@kp.org</email>
    </contact>
    <investigator>
      <last_name>Lou Fehrenbacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Scheiner</last_name>
      <email>Jonathan.Scheiner@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Virginia Borges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelle Sowers</last_name>
      <email>noelle.sowers@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Michael DiGiovanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Miller, MD</last_name>
      <email>mmiller@stamhealth.org</email>
    </contact>
    <investigator>
      <last_name>Steve Lo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist - South</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Main Line</last_name>
      <email>clinicaltrials@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Lowell Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center - Miami Beach</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juana Camus</last_name>
      <email>juana.camus@msmc.com</email>
    </contact>
    <investigator>
      <last_name>Elisa Krill-Jackson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Research Institute</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Beck</last_name>
      <phone>954-582-1850</phone>
      <email>pamelab@flcancercare.com</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Tan-Chiu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Conte</last_name>
      <email>dmc238@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Aruna Mani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialist, St. Petersburg/SCRI</name>
      <address>
        <city>St.Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Main Line</last_name>
      <email>clinicaltrials@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Gail Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Main Line</last_name>
      <email>clinicaltrials@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Marilyn Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachael Maynard</last_name>
      <email>rmaynar@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Elisavet Paplomata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Coples</last_name>
      <email>Susan.Coples2@northside.com</email>
    </contact>
    <investigator>
      <last_name>Amelia Zelnak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Regents Cancer Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Wall</last_name>
      <email>swall@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Shou-Ching Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Georgia Cancer Care (CGCC)</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Kerr</last_name>
      <email>jkerr@centralgacancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Sumrall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America (SeRMC)</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quin Boynes</last_name>
      <email>quin.boynes@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrystie Paul</last_name>
      <phone>312-942-3732</phone>
      <email>Chrystie_Paul@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Melody Cobleigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46628</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ensminger</last_name>
      <email>mensmi@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Michelle Loch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University MD Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Trait</last_name>
      <email>ntait@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Tkaczuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Steere</last_name>
      <email>lsteere@partners.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Vallieres</last_name>
      <email>pvallie9@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Doyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Mendenhall</last_name>
      <email>heather.mendenhall@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Padmaja Venuturumilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Green</last_name>
      <email>lori.green@allina.com</email>
    </contact>
    <investigator>
      <last_name>Michaela Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota - Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerri Anderson</last_name>
      <phone>612-626-6541</phone>
      <email>ander258@umn.edu</email>
    </contact>
    <investigator>
      <last_name>David Potter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists (NCS)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
    <investigator>
      <last_name>Margaret Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunterdon Medical Center (HMC)</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serena Schmitz</last_name>
      <email>schmitz.serena@hunterdonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Blankstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Francois</last_name>
      <email>dfrancoi@chpnet.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Malamud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-9446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Delli Bovi</last_name>
      <email>patricia.dellibovi@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Alison Stopeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Lansing</last_name>
      <email>katie_lansing@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Carey Anders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute (DCI) - Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Cummings</last_name>
      <email>sheryl.cummings@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Kimberly Blackwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University (ECU)</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Coghill</last_name>
      <email>coghilll@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Mahvish Muzaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Zimmerman</last_name>
      <email>Carla.Zimmerman@KinstonMD.com</email>
    </contact>
    <investigator>
      <last_name>Peter Watson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael McNeal</last_name>
      <email>michael.mcneal@akrongeneral.org</email>
    </contact>
    <investigator>
      <last_name>Esther Rehmus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Comprehensive Cancer Center (OSUCCC)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Wilson</last_name>
      <email>Debbie.Wilson@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Maryam Lustberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Moxon</last_name>
      <email>nicole.moxon@providence.org</email>
    </contact>
    <investigator>
      <last_name>Alison Conlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Bucher</last_name>
      <phone>503-418-9736</phone>
      <email>bucherj@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kathleen Kemmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates of NEPA</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeeAnn Haefele</last_name>
      <email>leeann.haefele@cancercarenepa.com</email>
    </contact>
    <investigator>
      <last_name>Kristen Liptock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (UPenn)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Savage</last_name>
      <email>Jessica.savage@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Amy Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Smith</last_name>
      <email>Paula.Smith@RoperSaintFrancis.com</email>
    </contact>
    <investigator>
      <last_name>Steven Akman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425-8900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Dangerfield</last_name>
      <email>danger@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Sara Giordano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont Cancer Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Reynolds</last_name>
      <email>justin.reynolds@wellmont.org</email>
    </contact>
    <investigator>
      <last_name>Asheesh Shipstone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Main Line</last_name>
      <phone>877-691-7274</phone>
      <email>Asksarah@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Erika Hamilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jannine Hewitt</last_name>
      <email>jannine.hewitt@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Vandana Abramson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders (SCRI)</name>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pool</last_name>
      <email>mpool@txcc.com</email>
    </contact>
    <investigator>
      <last_name>Robyn Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christie Eddins</last_name>
      <phone>713-794-4776</phone>
      <email>cseddins@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Stacy Moulder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Ortiz</last_name>
      <email>paortiz@covhs.org</email>
    </contact>
    <investigator>
      <last_name>Ibraham Shalaby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-San Antonio Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Davis</last_name>
      <email>deborah.davis@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Wilks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <email>goodwine@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Main Line</last_name>
      <phone>206-215-3086</phone>
      <email>cancerresearch@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Tanya Wahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henry Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Health - UW Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Koehn</last_name>
      <email>tmkoehn@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Ruth O'Regan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>AB T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofu Zhu</last_name>
      <email>Xiaofu.Zhu@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Xiaofu Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre, Calgary</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 3H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marny Yar</last_name>
      <email>Marny.Yar@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Sunil Verma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bliss Cancer Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Fuller</last_name>
      <email>efuller@easternhealth.ca</email>
    </contact>
    <investigator>
      <last_name>Joy McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre, Halifax</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rayson</last_name>
      <email>daniel.rayson@cdha.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Rayson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Bedard, MD</last_name>
      <phone>(416) 946-4534</phone>
      <email>philippe.bedard@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Philippe Bedard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital, Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Lara Rincon</last_name>
      <email>sheila.lara.rincon@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Cristiano Ferrario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendie Templeton</last_name>
      <email>Wendie.Templeton@saskcancer.ca</email>
    </contact>
    <investigator>
      <last_name>Muhammad Salim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre, Saskatoon</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rose Jackson</last_name>
      <email>Rose.Jackson@saskcancer.ca</email>
    </contact>
    <investigator>
      <last_name>Nayyer Iqbal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>November 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tucatinib</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>ARRY-380</keyword>
  <keyword>ONT-380</keyword>
  <keyword>HER2 Positive Breast Carcinoma</keyword>
  <keyword>HER2 Positive Locally Advanced Breast Cancer</keyword>
  <keyword>HER-2 Positive Breast Cancer</keyword>
  <keyword>HER-2 Positive Breast Carcinoma</keyword>
  <keyword>HER-2 Positive Locally Advanced Breast Cancer</keyword>
  <keyword>Recurrent Breast Carcinoma</keyword>
  <keyword>Stage IV Breast Cancer</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Metastatic Malignant Neoplasm in the Brain</keyword>
  <keyword>Brain Metastases in Breast Cancer</keyword>
  <keyword>Asymptomatic Brain Metastases in Breast Cancer</keyword>
  <keyword>Low Symptomatic Brain Metastases in Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
